RxDoctor Payments Data

Bhajan Dara, MD

Nephrology · Saint Louis, MONPI 1699708016

Payments from drug & device makers

$3,723in general payments, 2019–2025

Across 151 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$811
  • Mallinckrodt Hospital Products Inc.$683
  • Bayer$508
  • Amgen$358
  • Otsuka America Pharmaceutical, Inc.$219
  • Pfizer$197
  • plus $947 from 17 others

What the payments were for

  • Food & beverage$3,64598%
  • Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,723 in reported general payments places this provider in the 70th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$38,472
Medicare patients
101
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$77,019
EliquisApixaban48$46,947
JanuviaSitagliptin Phosphate39$37,776
JardianceEmpagliflozin30$33,857
XareltoRivaroxaban18$17,659
EntrestoSacubitril/Valsartan17$12,349
Semglee (Yfgn) PenInsulin Glargine-Yfgn22$8,025
Colchicine48$7,011
Cinacalcet Hcl11$6,947
Spiriva RespimatTiotropium Bromide12$6,046
Atorvastatin Calcium553$5,807
Calcium Acetate74$5,496
Chlorthalidone251$4,654
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$3,256
Midodrine Hcl29$3,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$811$77,01983 claims
PfizerEliquis$197$46,94748 claims
NovartisEntresto$178$12,34917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 253 nephrology providers in Missouri.

Other nephrology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →